Cisplatin was the first to be developed. In 1983 pediatric oncologist Roger Packer began incorporating cisplatin into adjuvant ... Cisplatin has been studied with Auger therapy to increase the therapeutic effects of cisplatin, without increasing normal ... "Cisplatin Use During Pregnancy". Drugs.com. 12 September 2019. Retrieved 25 February 2020. "Cisplatin". The American Society of ... It is suggested that an antibody reacting with a cisplatin-red-cell membrane is responsible for hemolysis. Cisplatin interferes ...
More than half of patients treated with cisplatin develop hearing impairment, but there are few guidelines on the monitoring, ... The risk of developing cisplatin-induced ototoxicity depends on various factors, including the cumulative dose of cisplatin, ... Cisplatin is one of the most commonly used chemotherapeutic agents for treating a variety of cancers, such as lung, bladder, ... The incidence of cisplatin-induced ototoxicity is estimated to be 36% of adult patients and 40% to 60% of pediatric patients. ...
Cisplatin is more effective than carboplatin for treating nonsmall cell lung cancer Peer-Reviewed Publication Journal of the ... Cisplatin is more effective than carboplatin for treating nonsmall cell lung cancer. Journal of the National Cancer Institute ... Cisplatin Versus Carboplatin for Patients With Metastatic Non - Small-Cell Lung Cancer - An Old Rivalry Renewed. J Natl Cancer ... Patients who received cisplatin lived slightly longer than those treated with carboplatin, with a median survival of 9.1 months ...
Physician reviewed cisplatin patient information - includes cisplatin description, dosage and directions. ... Cisplatin. Generic name: cisplatin [ sis-PLA-tin ]. Brand names: Platinol, Platinol-AQ, Platinol (Restricted Access). Dosage ... Cisplatin can harm an unborn baby if the mother or the father is using cisplatin. ... What is cisplatin?. Cisplatin is used together with other cancer drugs to treat bladder cancer, testicular cancer, or ovarian ...
CISPLATIN (UNII: Q20Q21Q62J) (CISPLATIN - UNII:Q20Q21Q62J) CISPLATIN. 1 mg in 1 mL. ... CISPLATIN (UNII: Q20Q21Q62J) (CISPLATIN - UNII:Q20Q21Q62J) CISPLATIN. 1 mg in 1 mL. ... CISplatin. INJECTION. 50 mg/50 mL (1 mg/mL) CISplatin doses greater than 100 mg/m2 once every 3 to 4 weeks are rarely used. ... CISplatin. INJECTION. 100 mg/100 mL (1 mg/mL) CISplatin doses greater than 100 mg/m2 once every 3 to 4 weeks are rarely used. ...
... about DBL Cisplatin Injection (cisplatin) intended for persons living in Australia. ... Before you are given DBL Cisplatin Injection. When you must not be given it Do not use DBL Cisplatin Injection if you have an ... Cisplatin may cause birth defects if you or your partner are being treated with it at the time of conception or, if cisplatin ... What DBL Cisplatin Injection is used for. DBL Cisplatin Injection belongs to a group of medicines known as antineoplastic or ...
More than half of patients treated with cisplatin-based chemotherapy develop hearing loss or tinnitus, which can be devastating ... Cisplatin is known to be highly ototoxic, the authors point out, but it achieves a very high cure rate when used for testicular ... The message is not that cisplatin should be avoided, but that "attention must be turned to survivorship, including an awareness ... More than half of patients with testicular cancer treated with first-line cisplatin-based chemotherapy in a recent study ...
Cisplatin is a type of chemotherapy drug used alone or in combination with other drugs to treat several advanced forms of ... Cisplatin is a type of chemotherapy drug used alone or in combination with other drugs to treat several advanced forms of ... Earlier this year, the health regulator had signed off on allowing cisplatin made by Chinas Qilu Pharmaceutical to be sold in ... The resumption of cisplatin manufacturing was first reported by Bloomberg News on Monday. ...
In combination therapy, cisplatin and cyclophosphamide are administered sequentially.. As a single agent, cisplatin should be ... Cisplatin is contraindicated in patients with a history of allergic reactions to cisplatin or other platinum-containing ... Cisplatin is contraindicated in patients with preexisting renal impairment. Cisplatin should not be employed in myelosuppressed ... Skin reactions associated with accidental exposure to cisplatin may occur. The use of gloves is recommended. If cisplatin ...
Regimens of radiotherapy and chemotherapy that contain cisplatin improve the rates of survival and progression-free survival ... cisplatin alone; cisplatin, fluorouracil, and hydroxyurea; and hydroxyurea alone -- in patients with locally advanced cervical ... Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer N Engl J Med. 1999 Apr 15;340(15 ... Patients were randomly assigned to receive one of three chemotherapy regimens: 40 mg of cisplatin per square meter of body- ...
The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment Mol Cancer Res. 2019 Apr;17(4):895-906. doi: ... We found that cisplatin treatment can potentially double the mutational burden in osteosarcoma, which has implications for ... In three of the four patients, the cisplatin signature accounted for ,40% of mutations detected in the metastatic samples. ... Mutations potentially acquired during cisplatin treatment included NF1 missense mutations of uncertain significance in two ...
A phase II trial associating the reference chemotherapy (pemetrexed plus cisplatin) with. bevacizumab is needed to ensure that ... A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for ... A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for ...
I had ear issues prior to chemo. I was sad to find that the chemo affected my hearing. I have lost some hearing in certain ranges. :( But..I am alive. :)
... and hearing loss is a well-recognized toxicity of cisplatin therapy. ... Cisplatin is effective in treating several types of childhood cancers (eg, CNS tumors, osteosarcoma, hepatoblastoma, ... Factors placing a child at increased risk for cisplatin ototoxicity include a cumulative cisplatin dose of 360 mg/m2 or greater ... Cisplatin ototoxicity initially presents as a loss of high-frequency hearing; it is typically bilateral and permanent and may ...
cisplatin from Neuroscience News features breaking science news from research labs, scientists and colleges around the world. ... A new study reports the chemotherapy drug cisplatin can kill sensory cells in the inner ear and cause permanent hearing loss.. ...
IU study finds many testicular cancer survivors have hearing loss after cisplatin therapy; nearly 20% lose significant hearing ... Hearing Loss Can Result from Cisplatin Therapy for Cancer. Jul 8, 2016 , Research , 5 , ... Platinum-based cisplatin is one of the most commonly used drugs in medical oncology, which unfortunately is ototoxic, or toxic ... For this study of cisplatin-related hearing loss, which was also covered by Sanjay Gupta, MD, in his "The Gupta Guide" column, ...
Cisplatin, a platinum compound, exerts its cytotoxic effects by coordinating to DNA where it inhibits both replication and ... Figure 3: XRD study of cisplatin microspheres.. 1-Cisplatin, 2-chitosan, 3-(cisplatin+chitosan), 4-microspheres EM-B ... Peaks of cisplatin crystals are also present in physical mixture (reduced in intensity). However, XRD pattern of the cisplatin ... The cisplatin microspheres showed higher FPF value compared to uncoated cisplatin both with and without lactose. The data ...
... like Alimta and Cisplatin. Learn more about some of the available options, their side effects and impact on prognosis at MAA ... alimta and cisplatin) against Cisplatin or Carboplatin with Gemcitabine, and found the median survival was 11 months for either ... Alimta is used in combination with cisplatin as a first-line therapy after a clinical trial showed pemetrexed plus Cisplatin ... Cisplatin has been on the market since 1978, and has been used to treat many types of cancers such as ovarian, testicular, lung ...
... plus cisplatin experienced a longer overall survival and improved progression-free survival vs fluorouracil plus cisplatin. ... Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal ... Gemcitabine Plus Cisplatin Provides Survival Benefit Over Fluorouracil Plus Cisplatin in Advanced Nasopharyngeal Carcinoma. ... The OS was significantly longer in the gemcitabine plus cisplatin arm than the fluorouracil plus cisplatin (HR, 0.72; 95% CI, ...
CAFs-Derived Exosomal miRNA-130a Confers Cisplatin Resistance of NSCLC Cells Through PUM2-Dependent Packaging ... F) IC50 of cisplatin in NFs, CAFs, A549, and A549-R cells. (G and H) Protein expressions of cisplatin resistance-associated ... Cisplatin-treated cells CM was prepared by culturing cells in serum-free DMEM supplemented with 10 μM cisplatin. ... CAFs-Derived Exosomes Confer Cisplatin Resistance of NSCLC Cells. Given the innate cisplatin resistance of CAFs, further ...
Sulforaphane protects against cisplatin-induced nephrotoxicity.. Guerrero-Beltrán CE, Calderón-Oliver M, Tapia E, Medina- ... Ya want broccoli with your cisplatin? (Hint: say "yes"!). Leave a Comment / Ask Your Doctor About, Chemotherapy, Corrective ... Cisplatin (cis-diamminedichloroplatinum II, CDDP) is a chemotherapeutic agent that induces nephrotoxicity associated with ...
... and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin ... Must have received 3-6 cycles of cisplatin-based chemotherapy as part of first-line (initial) chemotherapy.. *Prior POMBACE, ... Definition of one line of chemotherapy: One line of therapy can in some cases consist of 2 different cisplatin-based treatment ... Must have evidence of progressive or recurrent GCT (measurable or non-measurable) following one line of cisplatin-based ...
In combination with the chemotherapy agents, TCEE treatment further enhanced the tumor suppression efficiency of cisplatin and ... cisplatin and doxorubicin. In the present study, the TCEE treatment induced cell cycle arrest and suppressed cell growth on ... μM cisplatin or 0 to 5 μM doxorubicin in combination with 0.2 or 0.5 mg/mL TCEE for 48 hr. Both cisplatin and doxorubicin were ... Hep3B and HepJ5 cells were treated with 0 to 10 μM cisplatin or 0 to 5 μM doxorubicin in combination with 0 (black line) or 0.2 ...
... who presented a pathological complete response in the surgical specimen after neoadjuvant chemotherapy with cisplatin and ... Localized Colonic Small-Cell Carcinoma with Pathological Complete Response after Neoadjuvant Cisplatin and Etoposide: A Case ... "Localized Colonic Small-Cell Carcinoma with Pathological Complete Response after Neoadjuvant Cisplatin and Etoposide: A Case ... "Localized Colonic Small-Cell Carcinoma with Pathological Complete Response after Neoadjuvant Cisplatin and Etoposide: A Case ...
Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364-78. CrossRef Dasari S, Tchounwou PB ... Cisplatin impairs fluid and electrolyte absorption in rat small intestine: a role for 5‑hydroxytryptamine. Gut. 1999;44:174-9. ... Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364-78. CrossRef ... Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg. 2007;15:364-9. ...
... March 3, 2022. ... and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy," which was presented at the 2022 ASCO ...
Is cisplatin-ineligible, as defined by meeting any one of the cisplatin ineligibility criteria as per protocol. ... gemcitabine plus cisplatin] and RC + PLND) for participants with MIBC who are cisplatin-eligible. The dual primary hypotheses ... Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible ...
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma ... Background: First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma ... we recruited previously untreated patients with locally advanced or metastatic urothelial cancer who were cisplatin ineligible ...
Enfortumab Vedotin-ejfv Plus Pembrolizumab in Cisplatin-Ineligible Patients With Advanced Urothelial Cancer. By Matthew Stenger ... As stated by the investigators: "Cisplatin-based combination chemotherapy remains the standard of care for locally advanced or ... The median duration of response and median overall survival exceeding 2 years in a cisplatin-ineligible patient population make ... are not restricted by cisplatin eligibility, and warrant investigation as a first-line combination therapy in patients ...
Anti-tumor effect of cisplatin on oral cancer spheroids. (A) Schematic diagram from cisplatin addition to spheroid recovery. (B ... First, we evaluated the effect of cisplatin, which is widely used in oral cancer (Fig. 3A). Cisplatin has a cell-killing effect ... Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705-15 ... Cetuximab and Cisplatin Show Different Combination Effect in Nasopharyngeal Carcinoma Cells Lines via Inactivation of EGFR/AKT ...